Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
A clinical case of mucositis in child patient caused by Mycoplasma pneumoniae in combination with COVID-19 and reactivation of Epstein-Barr virus infection
https://doi.org/10.21508/1027-4065-2025-70-5-130-136
Abstract
Mycoplasma pneumoniae is one of the most significant bacterial pathogens in the structure of respiratory infections in children. In 5–10% cases the course of disease is “atypical” pneumonia, in other cases, mycoplasmosis occurs with symptoms of upper respiratory tract infection, often in combination with extrapulmonary manifestations; the frequency of the latter can reach 25%, the main are skin and mucous membrane lesions. Cases of arthritis, encephalitis, myelitis, severe anemia, myocarditis etc. are also described among other extrapulmomary manifestations. In 60% of children infected with Mycoplasma pneumoniae there is might becoinfection with other pathogens, in every fifth it is SARS-CoV-2. We present a clinical observation of a 16-year-old patient with acute respiratory tract infection and mucositis caused by combined infection with M.pneumoniae and SARS-CoV-2 with the reactivation of EBV infection.
About the Authors
V. A. Pozdnyak
Kazan State Medical University
Russian Federation
Russian Federation
420012, Kazan
S. V. Khaliullina
Kazan State Medical University
Russian Federation
Russian Federation
420012, Kazan
T. A. Aglyamova
Naberezhnye Chelny Infectious Diseases Hospital
Russian Federation
Russian Federation
423812, Naberezhnye Chelny
A. V. Zimina
Kazan State Medical University
Russian Federation
Russian Federation
420012, Kazan
V. A. Anokhin
Kazan State Medical University
Russian Federation
Russian Federation
420012, Kazan
References
1. GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024; 24(9): 974–1002. DOI: 10.1016/S1473-3099(24)00176-2
2. Rachina S.A., Kuprjushina O.A., Jasneva A.S., Volosovcova E.S., Strelkova D.A., Avdeev S.N. et al. What Do We Know about Mycoplasmal Pneumonia? Prakticheskaja Pul’monologija. 2023;(3): 20–30 (in Russ.) DOI: 10.24412/2409-6636-2023-13021
3. Korneenko E., Rog I., Chudinov I., Lukona-Gronskaya A., Kozyreva A., Belyaletdinova I. et al. Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023—February 2024. BMC Infectious Diseases. 2025; 25(1): 363. DOI: 10.1186/s12879-025-10712-0
4. Mycoplasma Pneumoniae Infections Have Been Increasing. October 18, 2024. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/ncird/whats-new/mycoplasma-pneumoniae-infections-have-been-increasing.html. Ссылка активна на 28.05.2025
5. Kutty P.K., Jain S., Taylor T.H., Bramley A.M., Diaz M.H., Ampofo K. et al. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis. 2019; 68(1): 5–12. DOI: 10.1093/cid/ciy419
6. Sun Y., Li P., Jin R., Liang Y., Yuan J., Lu Z. et al. Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022–2024: a nationwide cross-sectional study of over 1.6 million cases. Emerg Microbes Infect. 2025; 14(1): 2482703. DOI: 10.1080/22221751.2025.2482703
7. Kalantar H.T., Pooboni S. Mycoplasma pneumoniae-Induced Erythema Multiforme in an 11-Year-Old Boy: Diagnostic and Therapeutic Challenges. Cureus. 2025; 17(3):e79944. DOI: 10.7759/cureus.79944
8. Mycoplasma pneumoniae infection. Centre for Health Protection, Hong Kong. https://www.chp.gov.hk/en/healthtopics/content/24/21283.html. Ссылка активна на 28.05.2025
9. Lofgren D., Lenkeit C. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature. Spartan Med Res J. 2021; 6(2): 25284. DOI: 10.51894/001c.25284
10. Canavan T.N., Mathes E.F., Frieden I., Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015; 72(2): 239–245. DOI: 10.1016/j.jaad.2014.06.026
11. Samir S. Shah. Mycoplasma Pneumoniae. In: Principles and Practice of Pediatric Infectious Diseases 6th Edition. Editors S. Long, C. Prober, M. Fischer, D. Kimberlin. Philadelphia. Elsevier, 2023; 1041–1045
12. Marquart E., Kinaciyan T. Overlapping clinical presentation of Mycoplasma-induced rash and mucositis and drug-induced Stevens Johnson Syndrome: A case report. ID Cases. 2023; 33:e01888. DOI: 10.1016/j.idcr.2023.e01888
13. Frantz R., Huang S., Are A., Motaparthi K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021; 57(9): 895. DOI: 10.3390/medicina57090895
14. Mycoplasma-Induced Rash and Mucositis. American Academy of Ophthalmology. https://eyewiki.org/Mycoplasma-Induced_Rash_and_Mucositis. Ссылка активна на 28.05.2025
15. Ramien M.L. Stevens-Johnson syndrome in children. Curr Opin Pediatr. 2022; 34(4): 341–348. DOI: 10.1097/MOP.0000000000001146
16. Kechichian E., Dupin N., Wetter D.A., Ortonne N., Agbo-Godeau S., Chosidow O. Erythema multiforme. EClinicalMedicine. 2024; 77: 102909. DOI: 10.1016/j.eclinm.2024.102909
17. Kolganova N.I., Ovsjannikov D.Ju., Andzhel’ A.E., Birjukova M.V., Gitinov Sh.A, Gorev V.V. et al. Extrapulmonary manifestations of Mycoplasma pneumoniae infection in children. Detskie Infekcii. 2024; 23(2 (87)):45–51 (in Russ.) DOI: 10.22627/2072-8107-2019-18-3-5-10
18. Bukhari E.E., Alotaibi F.E., Bugshan A.S., Bakheet H.M., Binsufayan S.M., Alsaadi M.M. Mycoplasma pneumoniae-associated mucositis syndrome: A rare and clinically challenging disease in a Saudi child. J Taibah Univ Med Sci. 2017; 12(4): 356–359. DOI: 10.1016/j.jtumed.2016.12.002
19. Zhou Y., Wang J., Chen W., Shen N., Tao Y., Zhao R. et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2020; 20(1): 633. DOI: 10.1186/s12879-020-05356-1
20. Li F., Zhang Y., Shi P., Cao L., Su L., Fu P. et al. Mycoplasma pneumoniae and Adenovirus Coinfection Cause Pediatric Severe Community-Acquired Pneumonia. MicrobiolSpectr.2022; 10(2):e00026–22. DOI: 10.1128/spectrum.00026-22
21. Song Q., Xu B.P., Shen K.L. Effects of bacterial and viral co-infections of mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children’s Hospital between 2010 and 2014. Int J Clin Exp Med. 2015; 8(9): 15666–15674
22. Kim K., Jung S., Kim M., Park S., Yang H.J., Lee E. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(7):e2220949. DOI: 10.1001/jamanetworkopen.2022.20949
23. Mycoplasma pneumoniae Infection Surveillance and Trends. U.S. Centers for disease control and prevention. https://www.cdc.gov/mycoplasma/php/surveillance/index.html#cdcreference_4. Ссылка активна на 28.05.2025
24. Pereyre S., Goret J., Bebear C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016; 7: 974. DOI: 10.3389/fmicb.2016.00974
Review
For citations:
Pozdnyak V.A., Khaliullina S.V., Aglyamova T.A., Zimina A.V., Anokhin V.A. A clinical case of mucositis in child patient caused by Mycoplasma pneumoniae in combination with COVID-19 and reactivation of Epstein-Barr virus infection. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2025;70(5):130-136. (In Russ.) https://doi.org/10.21508/1027-4065-2025-70-5-130-136
Views:
166
Email this article 